Barclays PLC Buys 25,116 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Barclays PLC lifted its stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 282.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 34,003 shares of the biopharmaceutical company’s stock after acquiring an additional 25,116 shares during the period. Barclays PLC owned approximately 0.13% of Inovio Pharmaceuticals worth $197,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in INO. Bank of New York Mellon Corp bought a new stake in Inovio Pharmaceuticals in the second quarter worth $661,000. Dimensional Fund Advisors LP bought a new stake in Inovio Pharmaceuticals in the second quarter worth $605,000. Wellington Management Group LLP bought a new stake in Inovio Pharmaceuticals in the third quarter worth $379,000. State Street Corp lifted its stake in Inovio Pharmaceuticals by 11.7% in the third quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock worth $2,836,000 after purchasing an additional 51,414 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Inovio Pharmaceuticals by 6.7% in the third quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock worth $3,594,000 after purchasing an additional 38,833 shares during the last quarter. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Trading Up 5.8 %

Shares of NASDAQ INO opened at $2.20 on Wednesday. Inovio Pharmaceuticals, Inc. has a 1 year low of $1.74 and a 1 year high of $14.75. The company’s 50-day moving average is $2.93 and its 200 day moving average is $5.77.

Wall Street Analyst Weigh In

INO has been the subject of several recent research reports. Royal Bank of Canada lowered their price target on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research note on Friday, November 15th. Oppenheimer decreased their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. HC Wainwright decreased their price objective on shares of Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating on the stock in a research report on Monday, January 13th. Finally, JMP Securities restated a “market outperform” rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Inovio Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $12.40.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.